Medicare seniors get cheaper non-opioid pain drugs, no opioid gatekeeping

What it does

This bill modifies Medicare Part D (prescription drug coverage) to make non-opioid chronic pain medications more affordable and accessible for seniors. Starting in 2026, qualifying non-opioid pain drugs would have no deductible, be placed on the lowest cost-sharing tier, and cannot be subject to step therapy (forcing patients to try opioids first) or prior authorization delays. The bill covers seven specific chronic pain conditions: diabetic neuropathy, endometriosis, fibromyalgia, musculoskeletal pain, neuropathic pain, post-herpetic neuralgia, and trigeminal neuralgia.

Why we flagged it

The bill's core function is to reduce out-of-pocket costs and administrative barriers for a specific class of medications under Medicare Part D. It is a targeted benefit expansion, not a broad policy reform.

What the text implies

• The bill defines 'qualifying' drugs by wholesale acquisition cost threshold, but the threshold value is not specified in the provided text ('as determined by Sec...' appears incomplete), creating potential ambiguity about which drugs actually qualify.
• By prohibiting step therapy that requires opioid use first, the bill may increase opioid-sparing prescribing patterns, which could reduce opioid-related adverse events but may also shift cost burden to insurers if non-opioid alternatives are more expensive.
• The lowest-tier cost-sharing placement may incentivize formulary inclusion of non-opioid drugs, potentially affecting which medications insurers prefer to stock and promote.
• Low-income beneficiary protections are cross-referenced but not fully detailed in this text, leaving unclear whether the cost-sharing relief applies equally to dual-eligible (Medicare-Medicaid) beneficiaries.

Who it affects

Seniors and disabled Medicare beneficiaries with chronic pain gain direct financial relief through lower out-of-pocket costs and faster access to non-opioid alternatives. The removal of step therapy and prior authorization barriers reduces delays in receiving prescribed medications. The public health benefit of encouraging non-opioid pain management aligns with the opioid crisis response.

Who stands to gain

• pharmaceutical manufacturers of non-opioid pain medications
• specialty pharmaceutical companies
• biologics manufacturers

Named in the bill

Medicare Part D, Social Security Act, Food and Drug Administration (FDA), Bipartisan Budget Act of 2018, prescription drug plans, MA-PD plans

Where it stands

5 cosponsors: 3 Republicans, 2 Democrats.

• Oct 28, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Oct 28, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $280,000 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Steve Daines, the sponsor, reported $901,144 in PAC receipts in the 2026 cycle.

• Philanthropy Roundtable — $280,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.